English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech HealthCare & Pharma
商業化變現在即 開拓藥業核心產品優勢明顯
May 08, 2020 10:11 HKT
Novotech Selected as CRO for Karyopharm's COVID-19 Clinical Study
Apr 29, 2020 21:00 HKT
노보텍의 코로나19 임상시험 클라이언트, 아시아태평양 지역의 새로운 패스트트랙 심의과정의 혜택을 누리다
Apr 28, 2020 19:00 HKT
Novotech COVID-19 臨床試驗客戶受益於亞太地區新的快速審批流程
Apr 28, 2020 19:00 HKT
Novotech COVID-19 临床试验客户受益于亚太地区新的快速审批流程
Apr 28, 2020 19:00 HKT
Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes
Apr 28, 2020 19:00 HKT
GeoMap Clinical Patient Recruitment Platform Now Guarantees Enrollment Numbers
Apr 28, 2020 15:00 HKT
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果
Apr 27, 2020 09:53 HKT
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果
Apr 27, 2020 09:51 HKT
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Apr 27, 2020 09:50 HKT
研发强劲无惧竞争 康方生物后发制人底气足
Apr 24, 2020 18:21 HKT
研發強勁無懼競爭 康方生物後發制人底氣足
Apr 24, 2020 18:20 HKT
Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
Apr 24, 2020 16:22 HKT
ZALL Foundation partners Alibaba to launch ebook on Fangcang Shelter Hospitals in the fight against COVID-19
Apr 30, 2020 18:00 HKT
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Apr 24, 2020 10:00 HKT
Blockchain Holdings Enters into Definitive Agreement for Acquisition of COVID-19 Quarantine Management Product TRACEsafe
Apr 23, 2020 21:00 HKT
康方生物连获大基金青睐 香港嘉华集团入股
Apr 23, 2020 16:30 HKT
康方生物連獲大基金青睞 香港嘉華集團入股
Apr 23, 2020 16:29 HKT
重磅喜讯,基石药业首次递交中国大陆新药上市申请,国家药品监督管理局受理同类首创胃肠道间质瘤精准靶向药avapritinib的两个适应症上市申请
Apr 23, 2020 13:47 HKT
重磅喜訊,基石藥業首次遞交中國大陸新藥上市申請,國家藥品監督管理局受理同類首創胃腸道間質瘤精准靶向藥avapritinib的兩個適應症上市申請
Apr 23, 2020 13:46 HKT
<< Previous  Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: